PL2129377T3 - Ciekłe preparaty soli 4-[2-(4-metylofenylosulfanylo)fenylo]piperydyny - Google Patents

Ciekłe preparaty soli 4-[2-(4-metylofenylosulfanylo)fenylo]piperydyny

Info

Publication number
PL2129377T3
PL2129377T3 PL08715616T PL08715616T PL2129377T3 PL 2129377 T3 PL2129377 T3 PL 2129377T3 PL 08715616 T PL08715616 T PL 08715616T PL 08715616 T PL08715616 T PL 08715616T PL 2129377 T3 PL2129377 T3 PL 2129377T3
Authority
PL
Poland
Prior art keywords
methylphenylsulfanyl
piperidine
phenyl
salts
liquid formulations
Prior art date
Application number
PL08715616T
Other languages
English (en)
Inventor
Gudrun Lasskogen
Tine Bryan Stensbøl
De Diego Heidi Lopez
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PL2129377T3 publication Critical patent/PL2129377T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL08715616T 2007-03-20 2008-03-14 Ciekłe preparaty soli 4-[2-(4-metylofenylosulfanylo)fenylo]piperydyny PL2129377T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US1391807P 2007-12-14 2007-12-14
DKPA200701790 2007-12-14
PCT/DK2008/050062 WO2008113358A1 (en) 2007-03-20 2008-03-14 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
EP08715616A EP2129377B1 (en) 2007-03-20 2008-03-14 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine

Publications (1)

Publication Number Publication Date
PL2129377T3 true PL2129377T3 (pl) 2012-02-29

Family

ID=39327217

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08715616T PL2129377T3 (pl) 2007-03-20 2008-03-14 Ciekłe preparaty soli 4-[2-(4-metylofenylosulfanylo)fenylo]piperydyny

Country Status (26)

Country Link
US (1) US20100105730A1 (pl)
EP (2) EP2129377B1 (pl)
JP (1) JP5301474B2 (pl)
KR (1) KR20090130000A (pl)
AR (1) AR065796A1 (pl)
AT (1) ATE526966T1 (pl)
AU (1) AU2008228637B2 (pl)
BR (1) BRPI0808820A2 (pl)
CA (1) CA2684592C (pl)
CL (1) CL2008000797A1 (pl)
CO (1) CO6220958A2 (pl)
CY (1) CY1112285T1 (pl)
DK (1) DK2129377T3 (pl)
EA (1) EA019695B1 (pl)
ES (1) ES2373275T3 (pl)
HR (1) HRP20110844T1 (pl)
IL (1) IL200959A (pl)
MX (1) MX2009009388A (pl)
MY (1) MY148695A (pl)
NZ (1) NZ579717A (pl)
PL (1) PL2129377T3 (pl)
PT (1) PT2129377E (pl)
RS (1) RS52050B (pl)
SI (1) SI2129377T1 (pl)
TW (1) TWI405588B (pl)
WO (1) WO2008113358A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
HRP20140044T1 (hr) * 2007-06-15 2014-02-14 H. Lundbeck A/S 4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs)
RS53539B1 (sr) * 2009-04-24 2015-02-27 H. Lundbeck A/S Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina
WO2011136376A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
JP5787881B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163326A1 (de) 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2003033363A1 (en) 2001-10-16 2003-04-24 Medical Instill Technologies, Inc. Dispenser with sealed chamber and one-way valve for providing metered amounts of substances
DE10202367A1 (de) 2002-01-23 2003-09-25 Duerr Dental Gmbh Co Kg Applikator für flüssige oder viskose Substanzen
WO2004087156A1 (en) * 2003-04-04 2004-10-14 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
KR101367136B1 (ko) * 2007-07-27 2014-02-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 이의 제조 방법

Also Published As

Publication number Publication date
RS52050B (sr) 2012-04-30
CO6220958A2 (es) 2010-11-19
IL200959A (en) 2011-12-29
EP2129377A1 (en) 2009-12-09
EP2388004A1 (en) 2011-11-23
EA200970869A1 (ru) 2010-02-26
CA2684592C (en) 2013-11-12
ATE526966T1 (de) 2011-10-15
TWI405588B (zh) 2013-08-21
HRP20110844T1 (hr) 2011-12-31
BRPI0808820A2 (pt) 2014-08-19
EA019695B1 (ru) 2014-05-30
SI2129377T1 (sl) 2012-01-31
ES2373275T3 (es) 2012-02-01
AR065796A1 (es) 2009-07-01
TW200902083A (en) 2009-01-16
JP5301474B2 (ja) 2013-09-25
MX2009009388A (es) 2009-11-25
WO2008113358A1 (en) 2008-09-25
JP2010521500A (ja) 2010-06-24
DK2129377T3 (da) 2012-01-02
AU2008228637A1 (en) 2008-09-25
US20100105730A1 (en) 2010-04-29
KR20090130000A (ko) 2009-12-17
IL200959A0 (en) 2010-05-17
HK1140949A1 (en) 2010-10-29
EP2129377B1 (en) 2011-10-05
CL2008000797A1 (es) 2008-09-26
MY148695A (en) 2013-05-31
AU2008228637B2 (en) 2013-03-21
CA2684592A1 (en) 2008-09-25
PT2129377E (pt) 2011-12-23
NZ579717A (en) 2012-06-29
CY1112285T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
ZA201107731B (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
ZA201103495B (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
IL197420A0 (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
PL2167085T3 (pl) 4-[2-(4-metylofenylosulfanylo)fenylo]piperydyna do leczenia zespołu nadwrażliwości jelita grubego (ibs)
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
IL217914A0 (en) New compositions of 1-[2-(2'4-dimethyl-phenylsulfanyl)-phenyl]piperazine
SI2032531T1 (sl) Soli N-hidroksi-3-(4-(((2-(2-metil-1H-indol-3-il)etil)amino)metil)fenil)-2E-2 -propenamida
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
PL2722046T3 (pl) Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
ZA201003031B (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465
SI2608789T2 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
EP2537832A4 (en) METHOD OF PREPARING (E) -METHYL 2- (2- (6-CHLOROPYRIMIDIN-4-YLOXY) PHENYL] -3-METHOXYACRYLATE
HK1146903A (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
HK1167400A (en) Crystalline salts of methyl 2- ( (r) - ( 3-chloro phenyl) ( (r) -l- ( (s) -2- (methylamino) -3- ( (r) -tetrahydro-2h-pyran-3-yl) propylcarbamoyl )
EP2225255A4 (en) CRYSTALLINE FORMS OF 2- [2- (4-CHLOROPHENYL) ETHOXY] ADENOSINE